Please try another search
For the three months ended 31 March 2022, Biotoxtech Co Ltd revenues increased 24% to W8.7B. Net income decreased 62% to W268.5M. Revenues reflect Research Development Service segment increase of 23% to W8.3B, Venture Financing segment increase of 40% to W400.2M, South Korea segment increase of 22% to W8.32B, World (Region)-South Korea (Country) segment increase of 73% to W376.4M.
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Revenue | 8522.7 | 7151.61 | 8942.63 | 8014.03 |
Gross Profit | 218.55 | -603.65 | 1060.16 | 1186.85 |
Operating Income | -2857.93 | -2819.22 | -1268.1 | -1731.08 |
Net Income | -94.05 | -1727.08 | -2305.22 | -751.28 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Assets | 147036.24 | 130604.59 | 127567.89 | 123928.77 |
Total Liabilities | 98801.41 | 80976.99 | 75295.55 | 81301.21 |
Total Equity | 48234.83 | 49627.6 | 52272.34 | 42627.57 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -647.3 | -5672.21 | -7972.18 | -1946.53 |
Cash From Investing Activities | -34.69 | 2828.33 | 421.14 | -5193.14 |
Cash From Financing Activities | 14672.58 | 9149.52 | 6245.77 | 2954.31 |
Net Change in Cash | 13994 | 6304 | -1406.3 | -4112.25 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review